Share this @internewscast.com

The Food and Drug Administration may be one step closer toward what could be the first approval of a drug that uses the groundbreaking gene-editing tool CRISPR. 

The drug, called exa-cel, treats sickle cell disease, an inherited blood disorder that affects an estimated 100,000 people in the U.S., most of whom are Black, according to the Centers for Disease Control and Prevention. 

The illness causes the body’s red blood cells, usually disk-shaped, to take on a crescent or sickle shape. When this occurs, the cells can clump together, leading to clots and blockages in the blood vessels. This may result in a range of complications, including excruciating pain, trouble breathing or stroke.  

“The promise of a universally available, potentially curative option for individuals with sickle cell disease is revolutionary,” Dr. Biree Andemariam, hematologist and director of the New England Sickle Cell Institute at the University of Connecticut. Andemariam has consulted for Vertex Pharmaceuticals, which makes exa-cel. 

The illness is chronic and the only known cure is a bone marrow transplant from a donor, which carries the risk of rejection.

The gene-editing drug, from Vertex along with CRISPR Therapeutics, would eliminate the need for a donor. Instead, it works by changing the DNA in the patient’s blood cells.

Exa-cel uses CRISPR, a gene-editing tool that’s able to target certain stretches of DNA and snip them out, essentially deleting the unwanted section that, in the case of sickle cell disease, causes the cells to take on a crescent shape. 

On Tuesday, an FDA advisory committee reviewed the drug in an all-day meeting. These advisory meetings are usually one of the final steps before the agency decides whether to approve a drug. The FDA is expected to issue a final ruling by Dec. 8. 

No drug that uses CRISPR gene-editing — which was invented in 2009 — has been granted FDA approval. What’s more, Tuesday’s meeting looked different than past advisory committee meetings. In this case, the panel was not asked to evaluate the safety and effectiveness of Vertex’s drug, which is seeking approval for people age 12 and up with severe illness.

Instead, the focus was on the “off-target” effects of CRISPR — that is, when the technology makes cuts to other stretches of the DNA other than the intended target — and how the FDA should think about those risks moving forward.

It’s unclear what effects an off-target edit would have on a patient — it entirely depends on where it happens in the DNA. 

“Off-target editing does not necessarily mean that there’s going to be a bad outcome,” said committee member Scot Wolfe, a professor of molecular, cell and cancer biology at UMass Chan Medical School.

“There seems to be a lot of uncertainty, a lot of unknowns, about what these off-target changes might mean,” said committee member Lisa Lee, an epidemiologist and the director of scholarly integrity and research compliance at Virginia Polytechnic Institute and State University. 

“Are those unknowns more harmful than not allowing this to go forward?” Lee asked. 

Vertex Pharmaceuticals presented research findings on 46 people who received the treatment. Among the 30 patients with a minimum of 18 months of follow-up, 29 no longer experienced severe pain crises.

The company said there was no evidence of “off-target” effects from the therapy, but committee members questioned whether Vertex’s analysis was thorough enough.

“I’m not questioning that this product is important for our patients,” said committee member Dr. Joseph Wu, the director of the Stanford Cardiovascular Institute. “I’m just saying we’re at a point in which this thing is going to take off and wouldn’t it be nice to have more additional data.”

A big step forward but not a simple cure

Vertex has not disclosed the price of gene therapy but, if approved, it is expected to be extremely expensive, potentially costing as much as $2 million per patient, according to a report from the Institute for Clinical and Economic Review, a nonprofit group that helps determine fair prices for drugs. 

Dr. Stephan Grupp, chief of the therapy and transplant section of Children’s Hospital of Philadelphia, who consults for Vertex, said in an email that if approved, the step next would be to make sure patients can get access.

“I do think that they’re going to have to be a lot of questions answered regarding access,” Andemariam said.

While exa-cel is technically a one-time treatment, the process involves a number of steps. 

It starts by extracting stem cells from the patient’s blood. These stem cells are edited with exa-cel in the lab to delete the snippet of DNA that causes the cells to warp. Before these cells can be reinfused back into the patient, however, the patient must undergo chemotherapy to kill off cells that produce the sickle-shaped cells.

Follow NBC HEALTH on Twitter & Facebook.

Share this @internewscast.com
You May Also Like
Violent symbolism, threats steal show at nationwide 'No Kings' protests

Dramatic Imagery and Threats Dominate Headlines at Nationwide ‘No Kings’ Protests

On Saturday, millions across the nation participated in peaceful demonstrations during the…
Vance warns Hamas as Gaza peace plan's Civilian Military Cooperation Center opens

US Diplomat Vance Issues Strong Warning to Hamas Amid Launch of Gaza’s New Peace Initiative Center

Vice President JD Vance delivered a stern message to Hamas on Tuesday…
'Golden Bachelor' exclusive clip: Can Cindy get the answers she needs to move forward with Mel?

Exclusive Clip from ‘Golden Bachelor’: Will Cindy Find the Clarity She Needs to Progress with Mel?

This week on “The Golden Bachelor,” the excitement heightens as Mel embarks…
SJSO weighs in on Meta's new safety features for teen accounts

St. Johns Sheriff’s Office Reviews Meta’s Enhanced Safety Tools for Teens

Understanding the latest enhancements to parental controls on teen accounts is crucial,…
Immigration agents conducting sweep on NYC's famed Canal Street confronted by protesters

Immigration Agents Met with Protests During Canal Street Operation in NYC

NEW YORK (AP) — A planned immigration enforcement operation on Manhattan’s well-known…
Alleged stalker detained then released after girls’ hit-and-run deaths, arrested days later: officials

Shocking Twist: Teen Suspect Linked to Fatal Hit-and-Run Allegedly Swatted Victim’s Home Weeks Prior

A 17-year-old male, suspected of a fatal hit-and-run involving two teenage girls,…
'21st Century Digital Watergate': Another GOP Senator’s Phone Records Were Targeted by Biden’s DOJ

Biden’s DOJ Under Fire: Allegations of Targeting GOP Senator’s Phone Records in ‘Digital Watergate’ Scandal

Senator Ted Cruz of Texas has reportedly had his phone records subpoenaed…
Mickey Mouse surprises L.A. kids and teaches them the "Hot Dog!" dance from the 'Mickey Mouse Clubhouse+'

Mickey Mouse Delights L.A. Kids with a Surprise “Hot Dog!” Dance Lesson

LOS ANGELES — Amid joyful cheers and energetic music, Mickey Mouse made…
US Marshal, illegal alien shot in Los Angeles immigration operation

US Marshal and Undocumented Immigrant Injured During Los Angeles Immigration Enforcement Operation

In Los Angeles on Tuesday, a U.S. Marshal and an undocumented immigrant…
Putnam man arrested for threats toward neighbor

Putnam Resident Arrested for Alleged Threats Against Neighbor: Community Safety Concerns Rise

A man has been accused of threatening a neighbor and her family…
Blue city mayor rocked as gunfire hits home, says ‘none of us are immune’ from crime

Shocking Gunfire at Mayor’s Home Sparks Urgent Call for Action: Why No City is Safe from Crime Anymore

In a startling incident over the weekend, the residence of Stockton Mayor…
Alleged drunken driver blames fashion fail for crash that killed man on first date: report

Driver Accused of Fatal Crash Claims Wardrobe Malfunction Led to Tragedy on First Date

A tragic incident in Texas has taken an unusual turn as a…